Search Medical Condition
Please enter condition
Please choose location from dropdown

Mandeville, Louisiana Clinical Trials

A listing of Mandeville, Louisiana clinical trials actively recruiting patient volunteers.

RESULTS

Found (64) clinical trials

Phase

9.12 miles

Learn More »

Olanzapine With or Without Fosaprepitant Dimeglumine in Preventing Chemotherapy Induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic Chemotherapy

PRIMARY OBJECTIVES: I. To compare between the two study arms the proportion of patients with no nausea for the overall (0-120 hours post-chemotherapy), acute (0-24 hours post-chemotherapy), and delayed periods (24-120 hours post-chemotherapy) for patients receiving highly emetogenic chemotherapy (HEC). SECONDARY OBJECTIVES: I. To compare between the two study arms ...

Phase

9.12 miles

Learn More »

Pembrolizumab in Treating Patients With Stage III-IV High-Risk Melanoma Before and After Surgery

PRIMARY OBJECTIVES: I. To compare event-free survival (EFS) in patients with high-risk resectable melanoma randomized to neoadjuvant MK-3475 (pembrolizumab) with patients randomized to adjuvant MK-3475 (pembrolizumab). SECONDARY OBJECTIVES: I. To assess the frequency and severity of toxicities on each of the arms. II. To compare between arms overall survival (OS), ...

Phase

9.12 miles

Learn More »

Evaluation of Upadacitinib in Adolescent and Adult Patients With Moderate to Severe Atopic Dermatitis (Eczema)- Measure Up 1

The objective of this study is to assess the efficacy and safety of upadacitinib for the treatment of adolescent and adult participants with moderate to severe Atopic Dermatitis (AD) who are candidates for systemic therapy.

Phase

9.12 miles

Learn More »

A Study of Oral VT-1161 for the Treatment of Patients With Recurrent Vaginal Candidiasis (Yeast Infection)

Recurrent vulvovaginal candidiasis (RVVC), also known as recurrent yeast infections, is defined as at least 3 episodes of acute VVC in the past 12 months. Several properties of VT-1161 suggest that it might be a safer and more effective treatment for RVVC than other oral antifungal medicines. This study will ...

Phase

9.12 miles

Learn More »

To Evaluate the Safety and Tolerability of Atogepant 10mg 30 mg and 60 mg Once a Day for the Prevention of Migraine in Participants With Episodic Migraine

To evaluate the safety and tolerability of atogepant 30 mg and 60 mg once a day for the prevention of migraine in participants with episodic migraine.

Phase

9.12 miles

Learn More »

Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Versus Chemotherapy for Endometrial Carcinoma (ENGOT-en9 / MK-7902-001)

The purpose of this study is to compare the efficacy of pembrolizumab + lenvatinib to chemotherapy in female participants with Stage III, IV, or recurrent endometrial carcinoma. It is hypothesized that the combination of pembrolizumab + lenvatinib will be superior to chemotherapy for progression-free survival (PFS) per Response Evaluation Criteria ...

Phase

9.12 miles

Learn More »

Efficacy Safety and Tolerability of Atogepant for the Prevention of Chronic Migraine

This study will evaluate the efficacy, safety and tolerability of atogepant in participants with chronic migraine. This study includes a 12-week treatment period.

Phase

9.12 miles

Learn More »

Non-invasive Vagus Nerve Stimulation for the Prevention of Migraines

The study is a prospective randomized, multi-center, double-blind, parallel, sham-controlled study, designed for comparison of two parallel groups, gammaCore-Sapphire (active treatment) and a sham (inactive) treatment. The study period will begin with a four-week run-in period, during which there is no investigational treatment. The purpose of the run-in period will ...

Phase N/A

9.12 miles

Learn More »

Nivolumab and Ipilimumab Followed by Nivolumab Versus Cabozantinib and Nivolumab in Treating Patients With Metastatic Untreated Renal Cell Cancer

PRIMARY OBJECTIVES: I. To compare the overall survival (OS) in patients with metastatic renal cell cancer (RCC) treated with ipilimumab-nivolumab followed by either nivolumab versus cabozantinib-nivolumab. SECONDARY OBJECTIVES: I. To determine PFS of patients treated with nivolumab versus nivolumab-cabozantinib. II. To evaluate the 12-month complete response rate in patients treated ...

Phase

9.12 miles

Learn More »